China Universal Asset Management Co. Ltd. Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

China Universal Asset Management Co. Ltd. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 64.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 10,033 shares of the company’s stock after acquiring an additional 3,943 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Janux Therapeutics were worth $456,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in JANX. Capstone Investment Advisors LLC acquired a new stake in Janux Therapeutics in the 1st quarter valued at approximately $1,969,000. Lester Murray Antman dba SimplyRich purchased a new stake in Janux Therapeutics during the 1st quarter worth approximately $300,000. ProShare Advisors LLC acquired a new stake in Janux Therapeutics during the 1st quarter worth approximately $251,000. Lord Abbett & CO. LLC purchased a new position in Janux Therapeutics in the 1st quarter valued at approximately $20,420,000. Finally, Vanguard Group Inc. grew its stake in shares of Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after acquiring an additional 378,477 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the completion of the sale, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00. Following the sale, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 420,610 shares of company stock valued at $19,288,666 over the last quarter. Company insiders own 35.40% of the company’s stock.

Wall Street Analysts Forecast Growth

JANX has been the topic of a number of analyst reports. UBS Group initiated coverage on Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research report on Monday, August 19th. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics has an average rating of “Moderate Buy” and an average price target of $66.44.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX opened at $55.95 on Thursday. Janux Therapeutics, Inc. has a 12 month low of $5.65 and a 12 month high of $65.60. The firm has a market capitalization of $2.90 billion, a P/E ratio of -45.86 and a beta of 3.54. The company’s fifty day moving average price is $47.72 and its 200 day moving average price is $46.11.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. The business had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The business’s revenue for the quarter was up 709.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.